Michael Thorpy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael Thorpy has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Imran M. Ahmed
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
3 shared publications - Anne Marie Morse
Geisinger Commonwealth School of Medicine, Geisinger Medical Center, Janet Weis Children's Hospital Danville Pennsylvania USA
1 shared publication Bruce C. Corser
Sleep Management Institute, Cincinnati, OH
1 shared publicationChristopher Ontiveros
1 shared publicationColin Shapiro
Department of Psychiatry, Sleep and Alertness Clinic, Sleep Research Laboratory, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
1 shared publicationDan Chen
Clinical Development, Jazz Pharmaceuticals, Palo Alto, CA
1 shared publication
Latest Publications
- 1 April 2020
- Published by Elsevier in Sleep Medicine
- Vol. 68, 97-109
Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications
- 1 April 2020
- Published by Elsevier in Sleep Medicine
- Vol. 68, 97-109
Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications
- Open Access
- 17 January 2020
- Published by Springer Nature in CNS Drugs
- Vol. 34 (1) , 9-27
Recently Approved and Upcoming Treatments for Narcolepsy
Narcolepsy is a chronic, disabling neurologic disorder characterised by excessive daytime sleepiness (EDS) and, in up to 60% of patients, cataplexy. Treatments for narcolepsy are aimed at improving wakefulness (e.g. modafinil, armodafinil, stimulants), reducing cataplexy attacks (e.g. sodium oxybate, venlafaxine), and treating the symptoms of disturbed nocturnal sleep, sleep paralysis and sleep-related hallucinations (e.g. sodium oxybate). In general, medications that increase the release, or inhibit the reuptake, of norepinephrine or dopamine have wake-promoting effects and are useful in managing EDS, whereas medications that inhibit serotonin or norepinephrine reuptake have anticataplectic effects. Modulation of γ-aminobutyric acid B (GABAB) receptors or histamine H3 receptors (H3Rs) has effects on both EDS and cataplexy. Pitolisant, an H3R antagonist, and solriamfetol, a dopamine and norepinephrine reuptake inhibitor, are the most recently approved treatments for EDS associated with narcolepsy in the European Union (pitolisant) and the USA (pitolisant and solriamfetol). Several new agents are being developed and tested as potential treatments for EDS and cataplexy associated with narcolepsy; these agents include novel oxybate formulations (once-nightly [FT218]; low sodium [JZP-258]), a selective norepinephrine reuptake inhibitor (AXS-12), and a product combining modafinil and an astroglial connexin inhibitor (THN102). This review summarises the mechanisms of action, pharmacokinetics, efficacy, and safety/tolerability of recently approved and emerging treatments for narcolepsy.
- 17 January 2020
- Published by Springer Nature in CNS Drugs
- Vol. 34 (1) , 9-27
Open AccessRecently Approved and Upcoming Treatments for Narcolepsy
Narcolepsy is a chronic, disabling neurologic disorder characterised by excessive daytime sleepiness (EDS) and, in up to 60% of patients, cataplexy. Treatments for narcolepsy are aimed at improving wakefulness (e.g. modafinil, armodafinil, stimulants), reducing cataplexy attacks (e.g. sodium oxybate, venlafaxine), and treating the symptoms of disturbed nocturnal sleep, sleep paralysis and sleep-related hallucinations (e.g. sodium oxybate). In general, medications that increase the release, or inhibit the reuptake, of norepinephrine or dopamine have wake-promoting effects and are useful in managing EDS, whereas medications that inhibit serotonin or norepinephrine reuptake have anticataplectic effects. Modulation of γ-aminobutyric acid B (GABAB) receptors or histamine H3 receptors (H3Rs) has effects on both EDS and cataplexy. Pitolisant, an H3R antagonist, and solriamfetol, a dopamine and norepinephrine reuptake inhibitor, are the most recently approved treatments for EDS associated with narcolepsy in the European Union (pitolisant) and the USA (pitolisant and solriamfetol). Several new agents are being developed and tested as potential treatments for EDS and cataplexy associated with narcolepsy; these agents include novel oxybate formulations (once-nightly [FT218]; low sodium [JZP-258]), a selective norepinephrine reuptake inhibitor (AXS-12), and a product combining modafinil and an astroglial connexin inhibitor (THN102). This review summarises the mechanisms of action, pharmacokinetics, efficacy, and safety/tolerability of recently approved and emerging treatments for narcolepsy.
- Open Access
- 1 February 2019
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 43, 23-36
Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy
- 1 February 2019
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 43, 23-36
Open AccessNeurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy
- Top Cited PapersOpen Access
- 29 January 2019
- Published by Wiley in Annals of Neurology
- Vol. 85 (3) , 359-370
A randomized study of solriamfetol for excessive sleepiness in narcolepsy
Objective: Solriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy.Methods: Patients with narcolepsy with mean sleep latency p < 0.0001). At week 12, higher percentages of patients treated with solriamfetol 150 mg (78.2%) and 300 mg (84.7%) reported PGI‐C improvement relative to placebo (39.7%; both p < 0.0001). Adverse events ≥5% across all solriamfetol doses included headache (21.5%), nausea (10.7%), decreased appetite (10.7%), nasopharyngitis (9.0%), dry mouth (7.3%), and anxiety (5.1%).Interpretation: Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired wakefulness and excessive sleepiness in patients with narcolepsy. ANN NEUROL 2019;85:359–370.
- 29 January 2019
- Published by Wiley in Annals of Neurology
- Vol. 85 (3) , 359-370
Top Cited PapersOpen AccessA randomized study of solriamfetol for excessive sleepiness in narcolepsy
Objective: Solriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy.Methods: Patients with narcolepsy with mean sleep latency p < 0.0001). At week 12, higher percentages of patients treated with solriamfetol 150 mg (78.2%) and 300 mg (84.7%) reported PGI‐C improvement relative to placebo (39.7%; both p < 0.0001). Adverse events ≥5% across all solriamfetol doses included headache (21.5%), nausea (10.7%), decreased appetite (10.7%), nasopharyngitis (9.0%), dry mouth (7.3%), and anxiety (5.1%).Interpretation: Solriamfetol has the potential to be an important therapeutic option for the treatment of impaired wakefulness and excessive sleepiness in patients with narcolepsy. ANN NEUROL 2019;85:359–370.
- 1 March 2017
- Published by Elsevier in Sleep Medicine Clinics
- Vol. 12 (1) , 61-71
Reducing the Clinical and Socioeconomic Burden of Narcolepsy by Earlier Diagnosis and Effective Treatment
- 1 March 2017
- Published by Elsevier in Sleep Medicine Clinics
- Vol. 12 (1) , 61-71
Reducing the Clinical and Socioeconomic Burden of Narcolepsy by Earlier Diagnosis and Effective Treatment
- 1 January 2015
- Published by Springer Nature
- p. 107-116
Excessive Daytime Somnolence Associated with Parkinson’s Disease
- 1 January 2015
- Published by Springer Nature
- p. 107-116
Excessive Daytime Somnolence Associated with Parkinson’s Disease
- Open Access
- 1 December 2013
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. 5, 143-145
Toward a classification of medications for sleep and circadian rhythm disorders
Peer reviewed article authored by (Thorpy MJ, Roth T). Read article or submit your manuscript for publishing.
- 1 December 2013
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. 5, 143-145
Open AccessToward a classification of medications for sleep and circadian rhythm disorders
Peer reviewed article authored by (Thorpy MJ, Roth T). Read article or submit your manuscript for publishing.
- 1 June 2012
- Published by Elsevier in Sleep Medicine Clinics
- Vol. 7 (2) , 191-204
Differential Diagnosis of Hypersomnias
- 1 June 2012
- Published by Elsevier in Sleep Medicine Clinics
- Vol. 7 (2) , 191-204
Differential Diagnosis of Hypersomnias
- 24 September 2011
- Published by Springer Nature
- p. 297-314
Narcolepsy and Idiopathic Hypersomnia
- 27 August 2008
- Published by Taylor & Francis
- p. 21-33
Approach to the patient with a sleep complaint